Globeimmune (OTCMKTS:GBIM) and Assembly Biosciences (NASDAQ:ASMB) Critical Survey

Globeimmune (OTCMKTS:GBIM) and Assembly Biosciences (NASDAQ:ASMB) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, valuation, profitability, analyst recommendations, earnings, institutional ownership and dividends.

Valuation & Earnings

This table compares Globeimmune and Assembly Biosciences”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Globeimmune	N/A	N/A	N/A	N/A	N/A
Assembly Biosciences	$28.52 million	5.99	-$40.18 million	($5.58)	-3.99

Globeimmune has higher earnings, but lower revenue than Assembly Biosciences.

Analyst Ratings

This is a summary of recent ratings and recommmendations for Globeimmune and Assembly Biosciences, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Globeimmune	0	0	0	0	0.00
Assembly Biosciences	0	1	3	0	2.75

Assembly Biosciences has a consensus price target of $41.33, suggesting a potential upside of 85.68%. Given Assembly Biosciences’ stronger consensus rating and higher probable upside, analysts clearly believe Assembly Biosciences is more favorable than Globeimmune.

Volatility and Risk

Globeimmune has a beta of -275.17, indicating that its stock price is 27,617% less volatile than the S&P 500. Comparatively, Assembly Biosciences has a beta of 0.68, indicating that its stock price is 32% less volatile than the S&P 500.

Institutional and Insider Ownership

19.9% of Assembly Biosciences shares are owned by institutional investors. 23.5% of Globeimmune shares are owned by insiders. Comparatively, 5.3% of Assembly Biosciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Profitability

This table compares Globeimmune and Assembly Biosciences’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Globeimmune	N/A	N/A	N/A
Assembly Biosciences	-117.20%	-149.01%	-39.04%

Summary

Assembly Biosciences beats Globeimmune on 6 of the 10 factors compared between the two stocks.

About Globeimmune

GlobeImmune, Inc., a biopharmaceutical company, focuses on developing therapeutic products for cancer and infectious diseases based on proprietary Tarmogen platform. Its product candidate includes GS-4774, which is in Phase 2 trials for the treatment of patients with chronically infected with hepatitis B virus, as well as with oral antiviral suppressive therapy. The company is also involved in developing GI-6301 for the treatment of cancers expressing the brachyury protein; and GI-6207 that is in Phase 2 clinical trials to treat medullary thyroid cancer. In addition, it is involved in developing GI-4000, which is in Phase 2b clinical trials for the treatment of resected pancreas cancer; and is in Phase 2 clinical trial to treat non-small cell lung cancer, as well as is in Phase 2 clinical trial for the treatment of colorectal cancer. Further, the company is involved in developing various other product candidates targeting various infectious diseases that are in preclinical development stage, which include GI-19000 to treat tuberculosis; GI-2010 for the treatment of human immunodeficiency virus; and GI-18000 for hepatitis D virus infection. It has strategic collaborations with Gilead Sciences, Inc. and Celgene Corporation. The company was formerly known as Ceres Pharmaceuticals, Inc. and changed its name to GlobeImmune, Inc. in May 2001. GlobeImmune, Inc. was founded in 1995 and is headquartered in Louisville, Colorado. GlobeImmune, Inc. operates as a subsidiary of ImmunityBio, Inc.

About Assembly Biosciences

Assembly Biosciences, Inc., a biotechnology company, develops therapeutic candidates for the treatment of viral diseases. It develops ABI-5366, a long-acting herpes simplex virus (HSV) helicase-primase inhibitor that is in Phase 1a/1b clinical trial to treat recurrent genital herpes; ABI-1179, which is in Phase 1a/1b clinical trial for the treatment of recurrent genital herpes; and ABI-6250, a small molecule orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical trial. The company also develops ABI-4334, a next-generation capsid assembly modulator, which is in Phase 1b clinical trial for the treatment of hepatitis B virus (HBV). In addition, it develops an oral non-nucleoside polymerase inhibitor targeting transplant-related herpesviruses; and a small molecule interferon-a receptor agonist targeting HBV and HDV. The company has collaboration agreements with Gilead Sciences, Inc. and BeiGene, Ltd. The company was formerly known as Ventrus Biosciences, Inc. and changed its name to Assembly Biosciences, Inc. in June 2014. Assembly Biosciences, Inc. was incorporated in 2005 and is headquartered in South San Francisco, California.